DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Humanized Mouse Model Market by Type (Genetic, Cell-based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoiesis, Oncology, Immunology & Infectious diseases) & End User(Pharmaceutical & Biotech Companies, CRO)) - Global Forecast to 2021" report to their offering.
The Humanized Mouse Model Market is Projected to Reach USD 116.0 Million By 2021 from USD 73.3 Million in 2016, Growing at a CAGR of 9.6% in the Next Five Years (2016 to 2021)
Growing adoption of personalized medicine to fuel the demand for personalized mice models, continuous support in the form of investments and grants from the government and private sectors, and increase in R&D activities carried out by pharmaceutical and biotechnology companies are the key factors driving the growth of the market. However, regulations & laws formulated for ethical use of animals and increased use of rat models are restraining the growth of the market to a certain extent.
The global humanized mouse model market is segmented on the basis of type, application, end user, and region. In 2016, North America is expected to account for the largest share of the global humanized mouse model market, followed by Europe, Asia-Pacific, and the Rest of the World (RoW).
Asia-Pacific is projected to have the highest growth rate in the forecast period. The high growth rate of this segment can be attributed to factors such as increasing investments from the government and private sector in China, growing biomedical and medical research industry in Japan, growing presence of global players in India, and increasing pharmaceutical and biotech R&D activities in Korea.
The market witnesses high competitive intensity, as there are several big and many small firms with similar product offerings. These companies adopt various strategies (product launches, collaborations, agreements, partnerships, alliances, grants, licensing, contracts, acquisitions, and expansions) to increase their market shares and establish a strong foothold in the global market.
- Surge in the Number of Research Activities Involving Humanized Mouse Models
- Mice Models for Immunodeficiency Disorders
- Mice Models for Cancer
- Mice Models for Rare Diseases
- Growing Adoption of Personalized Medicine to Fuel the Demand for Personalized Mice Models
- Continuous Support in the Form of Investments And Grants from the Government And Private Sectors
- Funding/Grants By the National Institutes of Health (Nih)
- Funding/Grants Received from Other Government Bodies
- Increase in R&D Activities Carried Out By Pharmaceutical And Biotechnology Companies
- Regulations & Laws Formulated for Ethical Use of Animals
- The Animal Welfare Act (Awa)
- Public Health Service (Phs) Policy On Humane Care And Use of Laboratory Animals
- Increased Use of Rat Models
- Increased Production of Monoclonal Antibodies
- Advances in Zebrafish Model Development
- Alternative Methods of Animal Testing
- Limitations of Humanized Mouse Models
- Axenis S.A.S
- Champions Oncology, Inc.
- Crown Bioscience, Inc.
- Genoway S.A.
- Harbour Antibodies Bv (A Subsidiary of Harbour Biomed)
- Horizon Discovery Group Plc
- Humurine Technologies
- Ingenious Targeting Laboratory
- Taconic Biosciences, Inc.
- The Jackson Laboratory
- Trans Genic, Inc.
- Vitalstar Biotechnology Co., Ltd.
For more information about this report visit http://www.researchandmarkets.com/research/cl8l55/humanized_mouse